Literature DB >> 32971118

Heterogeneity of telomerase reverse transcriptase mutation and expression, telomerase activity and telomere length across human cancer cell lines cultured in vitro.

Marta Dratwa1, Barbara Wysoczanska1, Eliza Turlej2, Artur Anisiewicz2, Magdalena Maciejewska2, Joanna Wietrzyk2, Katarzyna Bogunia-Kubik3.   

Abstract

Promoter region of the telomerase reverse transcriptase gene (TERTp) constitutes a regulatory element capable to affect TERT expression (TE), telomerase activity (TA) and telomere length (TL). TERTp mutation status, TL, TA and TE were assessed in 27 in vitro cultured human cell lines, including 11 solid tumour, 13 haematological and 3 normal cell lines. C228T and C250T TERTp mutations were detected in 5 solid tumour and none of haematological cell lines (p = 0.0100). As compared to other solid tumour cell lines, those with the presence of somatic mutations were characterized by: shorter TL, lower TA and TE. Furthermore, cell lines carrying TERTp mutations showed a linear correlation between TE and TA (R = 0.9708, p = 0.0021). Moreover, haematological cell lines exhibited higher TE compared to solid tumour cell lines (p = 0.0007). TL and TA were correlated in both solid tumour (R = 0.4875, p = 0.0169) and haematological (R = 0.4719, p = 0.0095) cell lines. Our results based on the in vitro model suggest that oncogenic processes may differ between solid tumours and haematological malignancies with regard to their TERT gene regulation mechanisms.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Neoplastic haematological and solid tumour human cell lines; TERT expression; TERTp mutations; Telomerase activity; Telomerase reverse transcriptase; Telomere length

Year:  2020        PMID: 32971118     DOI: 10.1016/j.yexcr.2020.112298

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  6 in total

1.  Telomerase Reverse Transcriptase Promoter Mutations in Human Hepatobiliary, Pancreatic and Gastrointestinal Cancer Cell Lines.

Authors:  Masahiro Hirata; Koji Fujita; Shintaro Fujihara; Takaaki Mizuo; Ryota Nakabayashi; Toshiaki Kono; Daisuke Namima; Naoki Fujita; Hiroki Yamana; Hideki Kamada; Joji Tani; Hideki Kobara; Kunihiko Tsutsui; Yoko Matsuda; Masafumi Ono; Tsutomu Masaki
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

2.  Relationship between Telomere Length, TERT Genetic Variability and TERT, TP53, SP1, MYC Gene Co-Expression in the Clinicopathological Profile of Breast Cancer.

Authors:  Marta Dratwa; Barbara Wysoczanska; Wioletta Brankiewicz; Martyna Stachowicz-Suhs; Joanna Wietrzyk; Rafał Matkowski; Marcin Ekiert; Jolanta Szelachowska; Adam Maciejczyk; Mariusz Szajewski; Maciej Baginski; Katarzyna Bogunia-Kubik
Journal:  Int J Mol Sci       Date:  2022-05-05       Impact factor: 6.208

Review 3.  TERT-Regulation and Roles in Cancer Formation.

Authors:  Marta Dratwa; Barbara Wysoczańska; Piotr Łacina; Tomasz Kubik; Katarzyna Bogunia-Kubik
Journal:  Front Immunol       Date:  2020-11-19       Impact factor: 7.561

4.  TERT Promoter Mutation Analysis of Whole-Organ Mapping Bladder Cancers.

Authors:  Veronika Weyerer; Markus Eckstein; Pamela L Strissel; Adrian Wullweber; Fabienne Lange; Lars Tögel; Carol I Geppert; Danijel Sikic; Helge Taubert; Sven Wach; Bernd Wullich; Arndt Hartmann; Robert Stoehr; Johannes Giedl
Journal:  Genes (Basel)       Date:  2021-02-05       Impact factor: 4.096

5.  TERT genetic variability and telomere length as factors affecting survival and risk in acute myeloid leukaemia.

Authors:  Marta Dratwa; Barbara Wysoczańska; Aleksandra Butrym; Piotr Łacina; Grzegorz Mazur; Katarzyna Bogunia-Kubik
Journal:  Sci Rep       Date:  2021-12-02       Impact factor: 4.379

6.  BSG (CD147) Serum Level and Genetic Variants Are Associated with Overall Survival in Acute Myeloid Leukaemia.

Authors:  Piotr Łacina; Aleksandra Butrym; Eliza Turlej; Martyna Stachowicz-Suhs; Joanna Wietrzyk; Grzegorz Mazur; Katarzyna Bogunia-Kubik
Journal:  J Clin Med       Date:  2022-01-10       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.